Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
About this item
Full title
Author / Creator
Loomba, Rohit , Sanyal, Arun J. , Kowdley, Kris V. , Bhatt, Deepak L. , Alkhouri, Naim , Frias, Juan P. , Bedossa, Pierre , Harrison, Stephen A. , Lazas, Donald , Barish, Robert , Gottwald, Mildred D. , Feng, Shibao , Agollah, Germaine D. , Hartsfield, Cynthia L. , Mansbach, Hank , Margalit, Maya and Abdelmalek, Manal F.
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are...
Alternative Titles
Full title
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10718287
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10718287
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2304286
